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ABSTRACT
Background
Glucose-6-phosphate dehydrogenase (G6PD) is important in the control of oxidant stress in
erythrocytes, the host cells for Plasmodium falciparum. Mutations in this enzyme produce X-
linked deficiency states associated with protection against malaria, notably in Africa where the
A  form of G6PD deficiency is widespread. Some reports have proposed that heterozygous
females with mosaic populations of normal and deficient erythrocytes (due to random X
chromosome inactivation) have malaria resistance similar to or greater than hemizygous males
with populations of uniformly deficient erythrocytes. These proposals are paradoxical, and they
are not consistent with currently hypothesized mechanisms of protection.
Methods and Findings
We conducted large case-control studies of the A form of G6PD deficiency in cases of severe
or uncomplicated malaria among two ethnic populations of rural Mali, West Africa, where
malaria is hyperendemic. Our results indicate that the uniform state of G6PD deficiency in
hemizygous male children conferred significant protection against severe, life-threatening
malaria, and that it may have likewise protected homozygous female children. No such
protection was evident from the mosaic state of G6PD deficiency in heterozygous females. We
also found no significant differences in the parasite densities of males and females with
differences in G6PD status. Pooled odds ratios from meta-analysis of our data and data from a
previous study confirmed highly significant protection against severe malaria in hemizygous
males but not in heterozygous females. Among the different forms of severe malaria,
protection was principally evident against cerebral malaria, the most frequent form of life-
threatening malaria in these studies.
Conclusions
The A  form of G6PD deficiency in Africa is under strong natural selection from the
preferential protection it provides to hemizygous males against life-threatening malaria. Little
or no such protection is present among heterozygous females. Although these conclusions are
consistent with data from at least one previous study, they have not heretofore been realized
to our knowledge, and they therefore give fresh perspectives on malaria protection by G6PD
deficiency as an X-linked trait.
The Editors’ Summary of this article follows the references.
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Glucose-6-phosphate dehydrogenase (G6PD) is important
in the generation of reduced glutathione, a product key in the
control of oxidative damage in erythrocytes. Although
complete loss of this enzyme is presumably lethal, mutant
forms of G6PD with partially deﬁcient activity are common
and have been associated with protection against malaria.
Geographic distribution of these G6PD variants correlates
with historic distributions of the disease [1,2], and a mutant
allele (A ) encoding G6PD with 10%–50% of normal enzyme
activity is widespread in Africa [3–5]. However, conclusions
from case-control studies [5–7] and in vitro parasite culture
experiments [8–10] have been conﬂicting and have not been
reconciled satisfactorily with the differential expression of
G6PD*A  in males and females. For example, studies using
parasite densities but not clinical ﬁndings as indicators of
disease severity suggested resistance in heterozygous females
only, whereas hemizygous males paradoxically showed higher
parasitemias despite more severe enzyme deﬁciency [7]. A
report of near-equivalent protection against life-threatening
malaria in both males and females [5] has also been difﬁcult
to reconcile with the differential expression of G6PD
deﬁciency between the sexes, as hemizygous males would be
expected to show an advantage over heterozygous females
under at least one mechanism of protection currently
advocated [11].
The heavy impact of natural selection from malaria lies in
its severe manifestations that kill young children. In rural
villages of West Africa where malaria is hyperendemic and
adequate medication can be difﬁcult to obtain, virtually all
children experience malaria episodes early in life, and
approximately 20% die from the disease by age ﬁve [12]. A
tremendous selective advantage is therefore available to
children who can tolerate episodes of P. falciparum infection
and not have malaria progress from its uncomplicated form
to severe and fatal disease.
Following our demonstration of protection against severe
relative to uncomplicated malaria by hemoglobin (Hb) C in
Dogon children of Mali [13], we asked whether the A form of
G6PD deﬁciency might also protect against severe malaria,
and whether it might do so in a sex-speciﬁc manner. Here we
report the results of two case-control studies in Malian
villages where parasitization is ubiquitous and virtually all
children experience malaria in their early years.
Methods
Patient Populations and Malaria Case Definitions
Our case-control studies included two populations of
patients presenting to similarly equipped, physician-staffed
clinics: (i) 488 control individuals with uncomplicated malaria
and 67 patients with severe malaria from the Dogon of
Bandiagara, Mali, during two annual transmission seasons
(1997–1998); and (ii) 2,277 controls with uncomplicated
malaria and 365 patients with severe malaria from the
predominantly (82%) Malinke ´ inhabitants of Kangaba and
Kela, Mali, during four annual transmission seasons (2001–
2004). In accordance with World Health Organization guide-
lines, uncomplicated (mild) malaria was deﬁned by treatment-
seeking behavior for symptoms consistent with malaria (i.e.,
fever, headache) plus axillary temperature above 37.5 8C plus
observed parasite density below 500,000/ll. Severe (life-
threatening) malaria was deﬁned as either hyperparasitemia
( 500,000/ll) or the presence of any parasite density in
association with one or more of the following clinical criteria:
cerebral malaria (Blantyre coma score  2, witnessed con-
vulsions), severe anemia (hematocrit ,15% or hemoglobin
,5 g/dl [equivalent to 50 g/l]), respiratory distress, or
prostration (inability to sit unassisted in a child usually able
to do so) [14]. Patients with uncomplicated malaria were
treated with oral chloroquine (ﬁrst-line malaria treatment in
Mali during the study period) and monitored for clinical and
parasitologic treatment failures, which were treated with
either oral sulfadoxine–pyrimethamine (second-line malaria
treatment during the study period) or parenteral quinine, as
appropriate. Patients with severe malaria, or with uncompli-
cated malaria and parasite densities of 100,000–500,000/ll,
were treated parenterally with quinine. Study protocols were
approved by Institutional Review Boards of the Faculte ´d e
Me ´decine, de Pharmacie et d’Odontostomatologie, University
of Bamako and the National Institute of Allergy and
Infectious Diseases. Community permission and individual
written informed consent were provided by a parent or
guardian of all participating children, as described [15].
Laboratory Procedures and Statistical Analysis
Parasite densities in malaria patients were counted as
described [13]. The (A ) allele of the gene responsible for
G6PD deﬁciency in Mali was identiﬁed by restriction frag-
ment length polymorphism analysis of PCR-ampliﬁed DNA
samples. Blood was spotted onto strips of ﬁlter paper
(Schleicher & Schuell 907, http://www.arraying.com), and
DNA was extracted using the QIAamp kit (Qiagen, http://
www.qiagen.com). Under conditions intended to eliminate
risk of cross-contamination and with appropriate water-only
negative controls, exon 4 of G6PD was ampliﬁed using a
nested PCR protocol: 1 lg of genomic DNA was ﬁrst
ampliﬁed using primers 59-GTCTTCTGGGTCAGGGAT-39
(forward) and 59-GGAGAAAGCTCTCTCTCC-39 (reverse).
Denaturation at 94 8C for 2 min was followed by 45 cycles
of denaturation at 94 8C for 30 s, annealing at 60 8C for 30 s,
extension at 72 8C for 60 s, and ﬁnal extension at 72 8C
for 4 min. Nested ampliﬁcation was performed using
primers 59-CCTGTTCCCTCTGCCACA-39 (forward) and 59-
GGGGGTCTCAAGAAGTAC-39 (reverse). Denaturation at 94
8C for 2 min was followed by 35 cycles of denaturation at 94
8C for 30 s, annealing at 60 8C for 60 s, extension at 72 8C for
30 s, and a ﬁnal extension at 72 8C for 4 min. Ampliﬁcation
products were recovered with separate pipettors in labora-
tory areas apart from the PCR-preparation bench and
digested with the restriction endonuclease NlaIII (NEB,
http://www.neb.com) or its isoschizomer Hsp92II (Promega,
http://www.promega.com) to detect the G6PD*A mutation at
nucleotide position 202. Complete cutting of PCR product
identiﬁed hemizygous males and homozygous females; cutting
of half of the product identiﬁed heterozygous females. Hb
typing was performed by standard cellulose acetate electro-
phoresis (Helena Laboratories, http://www.helena.com) and in
some cases conﬁrmed by HPLC (D-10 instrument; Bio-Rad,
http://www.bio-rad.com).
Odds ratios (ORs), exact 95% conﬁdence intervals (CIs),
Fisher’s exact tests, and p-values were calculated by EpiInfo
2000 software (Centers for Disease Control and Prevention,
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(GraphPad Software, http://www.graphpad.com). Exact condi-
tional likelihood methods were used to calculate pooled ORs,
95% CIs, and two-sided p-values (StatsDirect version 2.5.7,
http://www.statsdirect.com). Assumptions of ﬁxed effects
meta-analysis were conﬁrmed by tests for homogeneity of
the ORs from the different geographic groups. Means of
log10-transformed P. falciparum densities were compared by
ANOVA (Epi Info2000, http://www.cdc.gov/epiinfo).
Results
Among all children presenting to our clinics with fever and
other symptoms of illness, our clinical and laboratory
determinations identiﬁed 3,197 with uncomplicated (n ¼
2,765) or severe (n ¼432) forms of malaria. Two observations
indicated the populations of children in the clinics were
representative of the populations at large. First, in Kela, the
one village in our program small enough to realistically
include children from all families, all but 112 of 1,288 age-
eligible children in the population (;50% of the cases in the
Malinke ´-predominant group of Table 1) were seen for
malaria and enrolled in our case-control study. From village
census information, we located the 112 children, met with
their families, and learned that reasons they had not come to
the clinic for malaria treatment were various, including that
they received other sources of care for uncomplicated
malaria (e.g., family self treatment or seeing a local
pharmacist), or that the children might have had malaria
without sufﬁciently intense symptoms to seek care (e.g.,
reduced symptoms in some cases because of the presence of
sickle trait) (unpublished data). These 112 children showed
proportions of G6PD*A  alleles in males and females (7/58 ¼
12.1% and 8/54 ¼ 14.8%, respectively) that did not differ
signiﬁcantly from those in the uncomplicated malaria groups
(152/1,078 ¼ 14.1% and 188/1,199 ¼ 15.7%; Fisher’s exact test
p-values 0.85 and 1.00, respectively). Second, in the larger
village of Bandiagara contributing to the Dogon study group,
we showed that the prevalence of Hb C in uncomplicated
malaria patients was the same as that in more than 7,000
individuals from the overall population [13], a ﬁnding
consistent with universal experience of Dogon children with
parasitization and malaria. Since the malaria cases from that
study also provided test samples for our present report, the
observed prevalence of G6PD A  in our uncomplicated
malaria control group likely reﬂects the prevalence of G6PD
A  in the Dogon population at large.
Table 1 presents the distributions of malaria cases in the
Dogon and Malinke ´-predominant groups by ethnicity, sex,
and G6PD genotype. These distributions show similar
prevalence of the G6PD*A  allele in controls with uncom-
plicated malaria among all children in both ethnic groups
(16.6% and 14.9%, respectively; Chi
2 p¼0.39). Relative to this
prevalence, the G6PD*A  allele is less frequent in the severe
malaria cases (7.5% and 11.0%, respectively; Chi
2 p¼0.01 for
the groups taken together).
The A form of G6PD deﬁciency in sub-Saharan Africa is a
sex-linked trait characterized by two mutations in the G6PD
gene-coding sequence on the X chromosome (nucleotide
changes A376G, resulting in an Asn ! Asp mutation, and
G202A, resulting in a Val ! Met mutation). In males with
G6PD A , all encoded copies of the enzyme are deﬁcient
because only one version of the X chromosome is present
(hemizygous state). However, G6PD A  females can have
either homozygous deﬁciency in which all encoded copies of
the enzyme are deﬁcient (because both of the two inherited X
chromosomes carry the mutant allele) or, more frequently, a
heterozygous, mosaic state of G6PD-deﬁcient and G6PD-
normal cells (because random inactivation of one of the two
inherited X chromosomes results in some cells with normal
enzyme and others with mutant enzyme). We therefore
examined our data for evidence of differential protection
against severe malaria by the uniform (hemizygous, homo-
zygous) states of G6PD deﬁciency relative to its mosaic state.
By stratiﬁed OR analysis of the case-control recruitments
from the Dogon and Malinke ´-predominant groups, we found
that the protection due to G6PD deﬁciency against severe
malaria occurs entirely in males (Table 1; pooled OR ¼ 0.42;
95% CI 0.23–0.73; p , 0.001). No evidence of protection
against severe malaria was evident among heterozygous
females mosaic for G6PD A  (pooled OR ¼ 1.00; 95% CI
0.62–1.55; p . 0.999). As a test for any evidence that ethnicity
might act as a confounder in these results, we repeated the
analysis with only malaria cases of identiﬁable Malinke ´
ethnicity (82%) from the Malinke ´-predominant group.
Calculations conﬁrmed reduced odds of severe malaria in
male children with G6PD A (OR¼0.37; 95% CI 0.18–0.70; p
¼ 0.001) but not in the heterozygous female children with
severe malaria (OR ¼ 1.00; 95% CI 0.59–1.64; p ¼ 0.99).
Children who survive repeated P. falciparum infections in
hyperendemic areas of sub-Saharan Africa eventually acquire
immunity against malaria that protects them against its
severe, life-threatening forms. This immunity is evident in
Table 1. Distribution of Severe and Uncomplicated Malaria in Recruited Children According to Ethnicity, Sex, and G6PD Genotype
Group Illness All Male Female
Deficient Normal Hemizygous Normal Heterozygous Homozygous Normal
Dogon Severe malaria 5 (7.5) 62 (92.5) 0 (0) 37 (100) 5 (16.7) 0 (0) 25 (83.3)
Uncomplicated malaria 81 (16.6) 407 (83.4) 34 (13.8) 213 (86.2) 46 (19.1) 1 (0.4) 194 (80.5)
Malinke ´ predominant Severe malaria 40 (11.0) 325 (89.0) 15 (7.7) 180 (92.3) 22 (12.9) 3 (1.8) 145 (85.3)
Uncomplicated malaria 340 (14.9) 1,937 (85.1) 152 (14.1) 926 (85.9) 148 (12.4) 40 (3.3) 1,011 (84.3)
Stratified analysis Pooled OR (95% CI) 0.42 (0.23–0.73) 1.00 (0.62–1.55) 0.51 (0.10–1.63)
p-Value ,0.001 .0.999 0.35
Data shown as number of cases (%) by sex and G6PD genotype.
doi:10.1371/journal.pmed.0040066.t001
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the ﬁrst few years of life [16,17]. Mutant hemoglobins also
contribute to protection against severe malaria in West
Africa [13,18,19]. To minimize the inﬂuence of the effects of
these forms of protection as potential confounding variables,
we determined the ORs for children both 5 y old and younger
and of normal HbAA type. Results from these calculations
(Table 2) provided even stronger evidence that G6PD A 
protects males against severe malaria (pooled OR¼0.28; 95%
CI 0.11–0.62; p , 0.001), whereas mosaic females again
showed no evidence of signiﬁcant protection (pooled OR ¼
0.92; 95% CI 0.49–1.65; p¼0.89). For homozygous females 5 y
old and younger in the Malinke ´-predominant group the OR¼
0.24; 95% CI 0.01–1.63; p¼0.21. G6PD-deﬁcient males among
children 5 y old or younger with uncomplicated malaria were
not signiﬁcantly older than their female counterparts (aged
3.17 6 1.29 y versus 2.95 6 1.23 y; p ¼ 0.22), so their
differential protection relative to heterozygous females could
not be explained by greater levels of age-dependent acquired
immunity.
In concert with analyses of the clinical presentations, we
compared the parasite densities of male and female children
5 y old or younger with different G6PD status. Among
children with malaria and HbAA type, no signiﬁcant differ-
ences were evident in males and females with or without
G6PD A  (Table 3). For uncomplicated cases the interaction
of sickle- or HbC-trait and G6PD deﬁciency and parasite
densities in male children was also not signiﬁcant (p ¼ 0.08).
Discussion
In rural villages of Mali, where virtually all young children
experience episodes of malaria, protective hemoglobino-
pathies and erythrocyte polymorphisms offer a tremendous
survival beneﬁt when they prevent progression of uncompli-
cated malaria to severe, life-threatening disease. Our study
was designed to test for protection by the A  form of G6PD
deﬁciency and determine whether the effect of this sex-linked
polymorphism would be more evident in male or female
children. Since children who never contract malaria are rare
at our study sites, we used case-control comparisons of severe
malaria patient ‘‘cases’’ against uncomplicated malaria
patient ‘‘controls’’ as described by Hayes et al. [20] for
epidemiological assessments of protection.
Our results from the Malinke ´ and Dogon children in two
regions 600 km apart show that G6PD A provides substantial
protection against severe malaria in hemizygous males but
little or no protection in heterozygous females. After
correcting for the confounding variables of age-dependent
acquired immunity and potential effects of hemoglobins C
and S, we calculate a pooled OR of 0.28 (95% CI 0.11–0.62)
for the males 5 y old and below in these two groups. While our
case-control design does not allow the calculation of relative
risk that would be available from a prospective cohort study,
the nearly complete recruitment of children with malaria in
the Kela region of our study suggests roughly two-thirds less
risk of severe malaria in young G6PD-deﬁcient relative to
G6PD-normal males. This level of protection from G6PD A 
in hemizygous males 5 y old and younger is comparable to
levels reported for hemoglobins C and S in certain West
African populations [13,18,19].
Because homozygous G6PD-deﬁcient females are relatively
rare, the number of these individuals that could be recruited
to our studies was low. Nevertheless, cohort sizes from the
Kela region were sufﬁciently large to detect a possible trend
to protection against severe malaria in these individuals. For
female children 5 y old and younger, the age range beneﬁting
most from this effect, the OR of this trend was calculated to
be 0.24 (95% CI 0.01–1.63), a value comparable to that for
young hemizygous males. Pooled OR calculations including
homozygous females 5 y old and younger from additional
regions were not possible as sufﬁcient recruitment numbers
were not available. Additional studies with larger groups will
be necessary to conﬁrm the signiﬁcance of this trend in
young homozygous females.
Two other studies have reported clinical investigations of
severe malaria in relation to G6PD A . In Nigeria, Gilles et al.
[6] observed a protective effect of G6PD A  against
convulsions or coma in male children 6 mo to 4 y of age;
numbers from the female cases were not considered statisti-
cally signiﬁcant for conclusions. In a later and much larger
study from The Gambia and Kenya, Ruwende et al. [5]
concluded that G6PD A  is associated with a 46%–58%
reduction in the risk of severe malaria for both hemizygous
males and heterozygous females. Those conclusions are
different from ours and led us to look more deeply into the
details of the authors’ data and analysis.
Our ﬁrst comment on the different conclusions from our
study and that of Ruwende et al. [5] concerns the control
groups. Ruwende et al. [5] compared cases of uncomplicated
or severe malaria in children up to 10 y of age against age-
Table 2. Distribution of Severe and Uncomplicated Malaria in HbAA Children  5 y According to Ethnicity, Sex, and G6PD Genotype
Group Illness Male Female
Hemizygous Normal Heterozygous Homozygous Normal
Dogon Severe malaria 0 (0) 27 (100) 4 (17.4) 0 (0) 19 (82.6)
Uncomplicated malaria 15 (14.6) 88 (85.4) 15 (15.5) 0 (0) 82 (84.5)
Malinke ´ predominant Severe malaria 7 (5.9) 111 (94.1) 13 (11.1) 1 (0.9) 103 (88.0)
Uncomplicated malaria 71 (15.5) 387 (84.5) 55 (12.3) 15 (3.4) 377 (84.3)
Stratified analysis Pooled OR (95% CI) 0.28 (0.11–0.62) 0.92 (0.49–1.65) 0.24
a (0.01–1.63)
p-Value ,0.001 0.89 0.21
Data shown as number of cases (%) by sex and G6PD genotype.
aOR with Fisher’s exact CI for Malinke ´-predominant group only, as no homozygotes with malaria were recruited in the Dogon group.
doi:10.1371/journal.pmed.0040066.t002
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malaria. Controls in Kenya included healthy community
children with or without asymptomatic parasitemia; controls
in The Gambia included inpatient and outpatient children
with nonmalarial illnesses and no P. falciparum parasitemia.
Comparative assessments of G6PD deﬁciency in cases of
severe versus uncomplicated malaria were not reported. In
contrast, our study was performed over two or four trans-
mission seasons in Malian villages where nearly every child
experienced malaria. Malaria-free ‘‘control’’ groups in this
context would have been highly skewed with confounding
variables if not impossible. Additionally, subjective thresholds
of treatment-seeking behavior for uncomplicated malaria can
vary among different village settings. We therefore focused
on the natural selection of G6PD deﬁciency that arises from
its ability to protect children against progression from
uncomplicated to severe, life-threatening malaria.
Ruwende et al. [5] provided data from The Gambia and
Kenya on the prevalence of G6PD A in children with severe
or uncomplicated malaria. Using these data in stratiﬁed
analysis, we calculate a pooled OR of 0.68 (95% CI 0.33–1.39;
p ¼ 0.32) for the protective effect of G6PD A  in the
hemizygous males, whereas for the heterozygous females the
pooled OR is 0.91 (95% CI 0.55–1.53; p ¼ 0.71) (Table S1).
Inclusion in these data of children older than 5 y and children
with Hb types other than AA could have masked a greater
trend to protection in the hemizygous males. The numbers of
recruited homozygous female cases were few and showed no
suggestion of protection.
Taken together, what do the different clinical studies of
severe malaria in relation to the G6PD A form of deﬁciency
indicate for an overall estimate of relative protection? In the
investigations producing the data from the Dogon, Malinke ´,
Kenyan, and Gambian populations, the study designs,
deﬁnitions of severe and uncomplicated malaria, and
methodological details were similar in their signiﬁcant
aspects and are, therefore, informative when analyzed
together. Earlier data from the Nigerian study [6] have to
be excluded because of that study’s highly restrictive
deﬁnition of severe malaria (only cases of convulsions or
coma in the presence of high fever and parasitemia  100,000/
ll). We therefore performed ﬁxed effects meta-analysis on the
data from Ruwende et al. [5] and from all children in our
study (data from Table 1, not Table 2, to avoid selective
exclusion of cases in this combined treatment). Pooled ORs
from all four sets of data conﬁrmed highly signiﬁcant
protection for hemizygous males (OR ¼ 0.51; 95% CI 0.33–
0.77; p , 0.001), but not for heterozygous females (OR¼0.96;
95% CI 0.68–1.34; p ¼ 0.87). This overall indication of
protection is probably underestimated for hemizygous HbAA
males who are 5 y old and younger, in light of our ﬁndings
that G6PD deﬁciency reduces the risk of severe malaria more
in this population.
We also performed meta-analysis of our data and those of
Ruwende et al. [5] for evidence of protection against two
leading forms of severe malaria highly fatal to African
children, cerebral malaria and severe anemia. Greater
numbers of cases of cerebral malaria were present in the
data than cases of severe anemia (Table S2). Results from this
analysis showed statistically signiﬁcant protection against
cerebral malaria for hemizygous males (pooled OR ¼ 0.44;
95% CI 0.24–0.77; p¼0.002) but not for heterozygous females
(pooled OR¼0.91; 95% CI 0.59–1.39; p¼0.76). No signiﬁcant
OR for protection could be demonstrated for the recruit-
ment groups with severe anemia (Table S2).
G6PD deﬁciency provides an important example of a sex-
linked locus that can be maintained in the absence of
heterozygote advantage [21]. Haplotype diversity and linkage
disequilibrium analysis has indicated that the G6PD*A allele
arose within the past 3,840–11,760 years and spread with
agriculture and malaria in Africa [22]. It is a balanced
polymorphism, as the protection provided by this G6PD
deﬁciency against severe malaria in hemizygous males (and
perhaps homozygous females) is also associated with risks of
life-threatening complications, e.g., neonatal jaundice and
devastating hemolytic crises precipitated by viral infections
or ingestion of medicinal or dietary oxidants [23]. In
hemizygous males and homozygous females, the risk of
hemolysis and protection against severe malaria would both
reﬂect the presence of uniformly G6PD-deﬁcient populations
of erythrocytes, whereas in heterozygous females the relative
reduction of these risks and lack of protection are attribut-
able to mosaic populations of G6PD-normal and G6PD-
deﬁcient erythrocytes circulating in the bloodstream. Our
evidence that the A  form of G6PD deﬁciency protects
against severe malaria in its uniform (hemizygous, homozy-
Table 3. Parasite Densities in Cases of Severe or Uncomplicated Malaria in Children  5 y According to Hb Type, Sex, and G6PD
Genotype
Illness Hb
Type
Males Females
Hemizygous Normal Heterozygous Homozygous Normal
Severe
malaria
AA 4.38 (3.91–5.17)
n ¼ 7, p ¼ 0.26
4.66 (4.27–5.06)
n ¼ 138
4.80 (4.78–5.11)
n ¼ 17, p ¼ 0.12
4.77
n ¼ 1, p ¼ 0.70
4.51 (4.14–4.94),
n ¼ 122
AS or AC 4.16 (3.59–4.73),
n ¼ 2, p ¼ 0.47
4.63 (4.14–5.06),
n ¼ 26
4.35 (3.54–4.76)
n ¼ 3, p ¼ 0.80
0 4.21 (3.47–5.06)
n ¼ 10
Uncomplicated
malaria
AA 4.30 (3.81–4.88)
n ¼ 86, p ¼ 0.79
4.28 (3.88–4.77)
n ¼ 475
4.21 (3.88–4.80)
n ¼ 70, p ¼ 0.30
4.12 (3.84–4.49)
n ¼ 15, p ¼ 0.29
4.30 (3.93–4.78)
n ¼ 459
AS or AC 4.04 (3.47–4.58)
n ¼ 22, p ¼ 0.08
4.32 (3.96–4.79),
n ¼ 98
4.04 (3.33–4.68)
n ¼ 11, p ¼ 0.80
0 4.24 (3.86–4.77),
n ¼ 94
Data shown are mean (interquartile range) of log10-transformed parasitemias/ll of whole blood by sex and G6PD genotype. p-Values reflect the probability that the difference between
two groups was observed by chance.
doi:10.1371/journal.pmed.0040066.t003
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consistent than do previous proposals with currently hy-
pothesized mechanisms of protection. Enhanced phagocyto-
sis of parasitized erythrocytes [11] or effects on the
pathogenic consequences of parasitized erythrocytes in the
microcirculation [24] would be expected to operate prefer-
entially in individuals whose erythrocytes are uniformly
deﬁcient in G6PD.
Supporting Information
Table S1. DistributionofUncomplicatedandSevereMalariaCasesina
Previously Reported Case-Control Study from The Gambia and Kenya
Data from Ruwende et al. [5] were used in stratiﬁed analysis to
calculate pooled ORs for the protective effect of the A  form of
G6PD deﬁciency in hemizygous males and heterozygous females
against severe malaria.
Found at doi:10.1371/journal.pmed.0040066.st001 (50 KB DOC).
Table S2. Distribution of Uncomplicated, Cerebral, and Severe
Anemia Malaria Cases in the Present Study and in a Previously
Reported Case-Control Study from The Gambia and Kenya
Data from the present study (Table 1) and from Ruwende et al. [5]
were used in ﬁxed effects meta-analysis to calculate pooled ORs for
the relative protection of the A  form of G6PD deﬁcient males and
females against cerebral malaria and severe anemia.
Found at doi:10.1371/journal.pmed.0040066.st002 (74 KB DOC).
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Background. ‘‘Favism’’ is a condition that results from a deficiency in an
enzyme called glucose-6-phosphate dehydrogenase (G6PD), and this
disorder is thought to be the commonest enzyme-deficiency disease
worldwide. The disease is named favism after the Italian word for broad
beans (fava), which cause a classic reaction when eaten by people with
G6PD deficiency. The G6PD enzyme is particularly important in red blood
cells, where it protects against damage that can be caused by certain
drugs or other stresses. There are a number of normal variants of G6PD,
with G6PD A and G6PD B being common in Africa. However, abnormal
mutations in the gene can lead to anemia as a result of the red blood
cells breaking down in response to certain drugs or types of food, or in
other situations. G6PD deficiency is not spread evenly around the world;
it is particularly common in Africa and the Mediterranean, and up to
20%–25% of people in certain African regions can have the condition.
Although there can be serious clinical outcomes from G6PD deficiency
that result from the red blood cells being broken down, G6PD deficiency
may protect against malaria.
Why Was This Study Done? The researchers here wanted to find out
whether, in regions where virtually all children get malaria during early
childhood, a mutation in G6PD A (written as G6PD A ) that leads to
G6PD deficiency protects children from having their malaria episodes
worsen into severe, life-threatening disease. They also wanted to look at
whether the degree of protection from G6PD A  deficiency differed
between boys and girls. The reason for looking at this had to do with the
genetics of G6PD deficiency. The gene coding for G6PD is carried on the
X chromosome, of which males have only one copy, whereas females
have two. Therefore, males will be G6PD deficient when they inherit only
one mutant gene, but females need to inherit two abnormal genes (or
have the normal gene turned off, which happens by a process known as
X-inactivation in a proportion of female cells).
What Did the Researchers Do and Find? This study was carried out in
two regions of Mali, West Africa, where malaria affects virtually all
children under the age of 5 years. The children recruited at each study
site came from two distinct cultural groups, the Dogon people of
Bandiagara and the Malinke ´ people of Kangaba and Kela. The researchers
studied children coming to the medical clinics in each area with either
uncomplicated malaria (i.e., mild symptoms) or severe malaria. All
patients were treated normally according to the standard practices for
this region. Blood samples were collected from each child in order to see
how many malaria parasites were in the blood, as well as to analyze each
patient’s DNA to work out whether they had a mutant form of the
G6PD*A gene that causes the G6PD A  form of deficiency.
Overall, 3,197 children were recruited into the study, 2,765 of whom
had uncomplicated malaria and 432 had severe malaria. In both ethnic
groups, children with severe malaria were much less likely to have the
mutant form of the G6PD*A gene than children with uncomplicated
malaria, showing that the gene mutation protected children from having
their malaria progress to severe malaria. The researchers then looked at
whether the protection given by the mutant forms of G6PD affected
boys and girls differently. The researchers found that protection against
severe malaria occurred in boys but not girls who had inherited one
mutant G6PD*A  gene.
What Do These Findings Mean? These data show that the mutation in
G6PD*A that leads to the G6PD A  deficiency gives children substantial
protection against severe malaria, but this protection seems to be the
case for boys and not girls who have only one mutant copy of the gene.
There seems to be around a two-thirds drop in risk of severe malaria in
boys with G6PD deficiency as compared to normal boys. At present the
reason for this difference in protection is not clear, because it is not
known how malaria parasites are affected by red blood cells that lack
G6PD activity.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040066.
  Medline Plus has an article on glucose-6-phosphate dehydrogenase
deficiency
  Wikipedia has an entry on glucose-6-phosphate dehydrogenase
deficiency (Wikipedia is a free internet encyclopedia that anyone can
edit)
  Information on malaria is available from the US Centers for Disease
Control
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